Medical big health track gold absorption capacity is still strong, the head mechanism continues to increase positions

"Pharmaceutical Network Industry Dynamics" October 13, Beijing Yizhuang Pharmaceutical SME Development Investment Center (Limited Partnership) completed the fund-raising.
The fund was jointly initiated by Saisheng Pharmaceuticals in association with Beijing Yitang Saiying Fund Management Co., Ltd., Beijing Yizhuang Investment Holdings Co., Ltd., Beijing Yizhuang International Investment and Development Co., Ltd., and Beijing Small and Medium Enterprises Venture Capital Guidance Fund, raising a capital of 230 million yuan.
the fund's main investment areas, the Pharmaceutical Small and Medium Development Fund intends to invest mainly in biopharmaceuticals, including biotechnology innovative drugs, high-end chemical innovation drugs, biomedical materials and so on.
this echoes Saisheng Pharmaceuticals' previous statement to integrate the company's related industries, upstream and downstream enterprises, and strengthen research and development and market control capabilities in these areas.
October 12, Fangsheng Pharmaceuticals announced that the company decided to jointly fund the establishment of Changsha Xingxing Health Investment Partnership (Limited Partnership) with Shanghai Investment, High-tech Ventures, Changxin Investment, High-tech Ventures, Doobang Consulting and Hunan Health and Pension Industry Investment Fund (Limited Partnership) (tentative name, based on industrial and commercial registration approval, "Health Investment Fund").
the total size of the health investment fund is 375 million yuan.
the establishment of the Health Investment Fund, the company hopes to use professional investment institutions in the biopharmaceutical and health industry upstream and downstream resources and fund-raising channels and professional investment judgment.
It is not difficult to see that the pharmaceutical health track gold absorption capacity is still strong, some analysts pointed out that from the current structure of A-share listed companies, the GEM alone has nearly 70 pharmaceutical production and research and development listed companies, the total market value of 1.2 trillion yuan, accounting for nearly 15% of the total market value of GEM.
the Shenzhen Stock Exchange's GEM may relax its financial targets for listing, allowing loss-making healthcare companies to go public after a year.
industry believes this will help to bring more margins of safety and investor confidence to investment in the sector.
at the same time as the medical health track is hot, the head mechanism is also constantly increasing the position.
Among them, Gaoyu Capital on October 12th again invested in medicine, was associed with CDMO enterprise Kailai Yingding increased by 4.4053 million shares, the allocation amount of 1 billion yuan, the lock-up period of 6 months, to become the largest buyer of Kailai Ying's nine granted objects.
based on public information, it is not difficult to find that Gao Gao capital in the pharmaceutical track continued to "buy and buy."
According to Wind data, from January 1 to July 13 this year, Gao's capital proposed to increase its stake in the A-share company has five, of which three belong to the pharmaceutical and biological industry, including Kelly Tai, Kailei Ying, health yuan.
Pharmaceutical Bio, which has previously taken a stake in the company, also includes Jindao Medical, Tagg Pharmaceuticals, Eyre Ophthalmology, Pharmaceutical Mingkangde, Gan Li Pharmaceuticals, Junshi Bio, Xinda Bio, Hanyu Pharmaceuticals, etc.
addition, the shareholder structure behind the upcoming listing of Jiahua Bio and Yunding Xinyao can also be seen in the capital.
incomplete statistics, so far, Gao's capital has invested in 100 enterprises in biomedicine, medical equipment, medical services, pharmaceutical retailing and other fields, including more than 100 Chinese enterprises.
total investment amounted to more than 120 billion yuan, and the total market value of investment enterprises exceeded 2.5 trillion yuan.
also worth mentioning that the seven private pharmaceutical companies invested by Gao Wei Capital are in the top 10 by market value of Hurun China's 100 Strong Healthy Private Enterprises 2020.
data show that GaoXuan Capital is a company specializing in asset management business, as a qualified foreign institutional investor engaged in securities investment activities, its management of China Value Fund focused on the Chinese business as the core, with long-term growth of listed companies.